YEVGENIY KHARITON to Health Status
This is a "connection" page, showing publications YEVGENIY KHARITON has written about Health Status.
Connection Strength
1.614
-
Health Status Benefits of Successful?Chronic Total Occlusion Revascularization Across the Spectrum?of?Left Ventricular Function: Insights From the OPEN-CTO Registry. JACC Cardiovasc Interv. 2018 11 26; 11(22):2276-2283.
Score: 0.536
-
Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry. Circ Cardiovasc Qual Outcomes. 2018 04; 11(4):e004668.
Score: 0.512
-
Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry. ESC Heart Fail. 2021 02; 8(1):710-713.
Score: 0.153
-
Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in?Heart?Failure With Reduced Ejection?Fraction. JACC Heart Fail. 2019 11; 7(11):933-941.
Score: 0.141
-
Impact of Telemonitoring on Health Status. Circ Cardiovasc Qual Outcomes. 2017 Dec; 10(12).
Score: 0.125
-
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021 11; 27(11):1954-1960.
Score: 0.041
-
Association between sacubitril/valsartan initiation and real-world health status trajectories over 18?months in heart failure with reduced ejection fraction. ESC Heart Fail. 2021 08; 8(4):2670-2678.
Score: 0.040
-
Association of Changes in Heart?Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF. JACC Heart Fail. 2019 07; 7(7):615-625.
Score: 0.035
-
Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Cardiol. 2017 12 01; 2(12):1315-1321.
Score: 0.031